Posted by Michael Wonder on 08 May 2023
BeiGene receives new approvals for Brukinsa (zanubrutinib) in China
6 May 2023 - Brukinsa is approved for first-line treatment for CLL/SLL and Waldenström's macroglobulinaemia in China and has multiple approved indications in more than 65 markets worldwide.
BeiGene today announced the China NMPA approved four applications for Brukinsa (zanubrutinib), the company’s Bruton’s tyrosine kinase inhibitor, including two supplemental new drug applications for treatment-naïve adults with chronic lymphocytic leukaemia or small lymphocytic lymphoma and Waldenström's macroglobulinaemia, and two supplemental applications for conversions from conditional approval to regular approval.
